NVCT - Nuvectis Pharma, Inc.

Insider Purchase by Mosseri Marlio Charles (10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Mosseri Marlio Charles, serving as 10% owner at Nuvectis Pharma, Inc. (NVCT), purchased 154,770 shares at $6.18 per share, for a total transaction value of $957,083.00. Following this transaction, Mosseri Marlio Charles now holds 3,245,897 shares of NVCT.

This purchase represents a 5.00% increase in Mosseri Marlio Charles's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, October 23, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, October 29, 2025, 6 days after the trade was made.

Nuvectis Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mosseri Marlio Charles

10%

Marlio Charles Mosseri is a prominent biotech investor and former pharmaceutical executive recognized as a 10% owner of Nuvectis Pharma, Inc. (NVCT).[[1]](https://www.gurufocus.com/insider/232757/marlio-charles-mosseri)[[5]](https://www.nasdaq.com/press-release/smart-money-quietly-loading-160m-oncology-stock-nuvectis-pharma-next-breakout-biotech) He has demonstrated significant commitment through extensive insider purchases, including 33,442 shares on June 18, 2025, for $269,543, 240,000 shares on February 7, 2025, for $1,200,000, and a total of 23 buys with no sells over five years, holding 2,976,203 shares valued at over $24 million as of mid-2025.[[1]](https://www.gurufocus.com/insider/232757/marlio-charles-mosseri)[[3]](https://www.quiverquant.com/news/Insider+Purchase:+10%25+owner+at+$NVCT+Buys+240,000+Shares) Mosseri's ownership reflects strategic accumulation in the oncology-focused biotech firm, with his mailing address listed in London, UK.[[1]](https://www.gurufocus.com/insider/232757/marlio-charles-mosseri) While specific career highlights and education details are limited in public records, his status as a key shareholder alongside executives like Chairman & CEO Ron Bentsur underscores his influence in the sector.[[1]](https://www.gurufocus.com/insider/232757/marlio-charles-mosseri)[[5]](https://www.nasdaq.com/press-release/smart-money-quietly-loading-160m-oncology-stock-nuvectis-pharma-next-breakout-biotech)

View full insider profile →

Trade Price

$6.18

Quantity

154,770

Total Value

$957,083.00

Shares Owned

3,245,897

Trade Date

Thursday, October 23, 2025

122 days ago

SEC Filing Date

Wednesday, October 29, 2025

Filed 6 days after trade

HEALTHCAREBIOTECHNOLOGY

About Nuvectis Pharma, Inc.

Company Overview

No company information available
View news mentioning NVCT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/972520

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime